Skip to content

2024 February 1 release
Compare
Choose a tag to compare
@brendanreardon brendanreardon released this 01 Feb 17:38
· 13 commits to main since this release
v.2024-02-01
0b2dc4d
This commit was created on GitHub.com and signed with GitHub’s verified signature.
GPG key ID: B5690EEEBB952194
Verified
Learn about vigilant mode.

Added entries:

  • (FDA) BRAF p.V600E/K and sensitivity to vemurafenib for patients with Erdheim-Chester disease.

Revised entries:

  • (FDA) BRCA1/2 somatic variants and sensitivity to rucaparib for patients with fallopean tube cancer had the oncotree term updated to High-Grade Serous Fallopian Tube Cancer.
  • (FDA) FGFR3 fusions, p.R248C, p.S249C, p.G370C, and p.Y373C and sensitivity to erdafitinib for patients with urothelial carcinoma received an updated approval.
  • "Oncogenic Mutations" was removed from the variant_annotation field from all 10 records with that value.

Removed entries:

  • (FDA) FGFR2 fusions and sensitivity to erdafitinib for patients with urothelial carcinoma. The FDA amended their prior accelerated approval for erdafitinib, removing susceptible FGFR2 alterations from the indication.
Assets 2
Loading